Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency by.

Slides:

Advertisements

Similar presentations

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.

Advertisements

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,

The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo by Vicky Louise Morrison, Matthew MacPherson,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

TCR-MHC-peptide(s): in vivo veritas

Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Finding a diamond in the (mouse is) rough

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

by Nataliya Melnyk, and Jonathan Harrison

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Even Individuals Considered as Long-Term Nonprogressors Show Biological Signs of Progression After 10 Years of Human Immunodeficiency Virus Infection by.

Genetic sequence analysis of inherited bleeding diseases

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

An event of shear importance

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

How we choose factor VIII to treat hemophilia

Anti–factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome by Mihály Józsi, Stefanie Strobel, Hans-Martin.

by Monica Galli, Luisa Ruggeri, and Tiziano Barbui

by Sabah Sallah, and Jim Y. Wan

by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Robert McMillan, Jennifer Lopez-Dee, and Joseph C. Loftus

Primary testicular lymphoma

The sting of WASP deficiency: autoimmunity exposed

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Blocking VWF platelet binding to treat TTP

Platelet satellitism as a cause of spurious thrombocytopenia

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Molecular Mechanism of a Mild Phenotype in Coagulation Factor XIII (FXIII) Deficiency: A Splicing Mutation Permitting Partial Correct Splicing of FXIII.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Anergy: the CLL cell limbo

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes by Edward N. van den Brink, Ellen A. M. Turenhout,

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Plasma biomarker concentrations between study groups.

Actin assembly in response to thrombin.

by Wendy Lim, Sara K. Vesely, and James N. George

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Overcoming “aspirin resistance” in MPN

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

How I treat thrombocytopenia in pregnancy

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

A binding relationship with thrombin

Interaction of platelet-decorated VWF strings with leukocytes and infected red blood cells in vitro. Interaction of platelet-decorated VWF strings with.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Balancing bleeding in brain metastases

Anti–IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and.

Cold agglutinin disease

Presentation transcript:

Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency by Éva Ajzner, Ágota Schlammadinger, Adrienne Kerényi, Zsuzsanna Bereczky, Éva Katona, Gizella Haramura, Zoltán Boda, and László Muszbek Blood Volume 113(3): January 15, 2009 ©2009 by American Society of Hematology

Factor XIII levels in the patient's plasma and platelets, and the fate of factor XIII added to the patient's plasma in vitro and in vivo. Ajzner É et al. Blood 2009;113: ©2009 by American Society of Hematology

The binding of the patient's IgG to FXIII subunits. Ajzner É et al. Blood 2009;113: ©2009 by American Society of Hematology